Search Results - "LEONARD, J P"

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity by Cheng, S, Ma, J, Guo, A, Lu, P, Leonard, J P, Coleman, M, Liu, M, Buggy, J J, Furman, R R, Wang, Y L

“…Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a…”
Get full text

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study by Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I.

“…Background: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in…”
Get full text

Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors by Thompson, C.A., Charlson, M.E., Schenkein, E., Wells, M.T., Furman, R.R., Elstrom, R., Ruan, J., Martin, P., Leonard, J.P.

“…We aimed to assess anxiety and the psychological impact of routine surveillance scans in long-term survivors of adult aggressive lymphoma. In this…”
Get full text

Characterization of ZnO nanoparticle suspension in water: Effectiveness of ultrasonic dispersion by Chung, S.J., Leonard, J.P., Nettleship, I., Lee, J.K., Soong, Y., Martello, D.V., Chyu, M.K.

“…Suspensions of ZnO nanoparticles in water were prepared with the two-step powder dispersion process using several methods of ultrasonication. The dispersion of…”
Get full text

Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma by Ruan, J., Hajjar, K., Rafii, S., Leonard, J. P.

“…Angiogenesis, the growth of new blood vessels, requires dynamic expansion, assembly and stabilization of vascular endothelial cells in response to…”
Get full text

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness by Czuczman, M.S., Leonard, J.P., Jung, S., Johnson, J.L., Hsi, E.D., Byrd, J.C., Cheson, B.D.

“…This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular…”
Get full text

Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma by Elstrom, R.L., Leonard, J.P., Coleman, M., Brown, R.K.J.

“…Positron emission tomography (PET) is more accurate than computed tomography (CT) in staging and restaging of lymphoma, but both are considered necessary…”
Get full text

Toxicity burden score: a novel approach to summarize multiple toxic effects by Lee, S.M., Hershman, D.L., Martin, P., Leonard, J.P., Cheung, Y.K.

“…Toxicity data from cancer trials are summarized into a single outcome, dose-limiting toxicity (DLT), which does not account for multiple lower grade toxic…”
Get full text

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma by Leonard, JP, Friedberg, JW, Younes, A, Fisher, D, Gordon, LI, Moore, J, Czuczman, M, Miller, T, Stiff, P, Cheson, BD, Forero-Torres, A, Chieffo, N, McKinney, B, Finucane, D, Molina, A

“…Background: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest…”
Get full text

Choice of Ontario high schools and student sorting by ability by Leonard, P. S. J.

“…To what extent can offering more choice in schooling lead to 'cream skimming,' or the sorting of students by ability? I study whether increased choice leads to…”
Get full text

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib by Yang, C, Lu, P, Lee, F Y, Chadburn, A, Barrientos, J C, Leonard, J P, Ye, F, Zhang, D, Knowles, D M, Wang, Y L

“…Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Although some patients can be cured by current therapies, novel agents…”
Get full text

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies by Martin, P., Chadburn, A., Christos, P., Furman, R., Ruan, J., Joyce, M.A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E.J., Shore, T.B., Schuster, M.W., Ely, S., Knowles, D.M., Chen-Kiang, S., Coleman, M., Leonard, J.P.

“…Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3–4 years. As a consequence, first-line…”
Get full text

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 by Leonard, J P, Waldburger, K E, Goldman, S J

“…Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system that can be transferred to naive mice via CD4+ T cells…”
Get full text

Four-zone solidification microstructure formed by laser melting of copper thin films by Zhong, R., Kulovits, A., Wiezorek, J.M.K., Leonard, J.P.

“…Polycrystalline copper film microstructures produced by laser melting and rapid lateral solidification are analyzed using transmission electron microscopy. The…”
Get full text

Electron microscopy of geometrically confined copper thin films after rapid lateral solidification by Kulovits, A., Zhong, R., Wiezorek, J.M.K., Leonard, J.P.

“…We have used transmission electron microscopy and scanning electron microscopy to study the microstructure in polycrystalline 200 nm thick copper thin films…”
Get full text

Iron losses under PWM excitation using a dynamic hysteresis model and finite elements by Leonard, P.J., Marketos, P., Moses, A.J., Lu, M.

“…A dynamic hysteresis model is used with a 2-D magnetic vector potential finite element formulation. The scheme models traditional eddy current, static BH and…”
Get full text

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) by Martin, P., Jung, S.-H., Pitcher, B., Bartlett, N.L., Blum, K.A., Shea, T., Hsi, E.D., Ruan, J., Smith, S.E., Leonard, J.P., Cheson, B.D.

“…This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma…”
Get full text

Elitek™-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 by NAVOLANIC, P. M, PUI, C-H, MCCUBREY, J. A, LARSON, R. A, BISHOP, M. R, PEARCE, T. E, CAIRO, M. S, GOLDMAN, S. C, JEHA, S. C, SHANHOLTZ, C. B, LEONARD, J. P

“…Renal precipitation of uric acid associated with tumor lysis syndrome (TLS) is a major complication in the management of leukemia, lymphoma, and other…”
Get full text

Suppression of dewetting phenomena during excimer laser melting of thin metal films on SiO2 by KLINE, J. E, LEONARD, J. P

“…Pulsed excimer laser irradiation has been used to fully melt 200 nm films of elemental Au and Ni on SiO2 substrates. With the use of a capping layer of SiO2…”
Get full text

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies by Leonard, J P, Goldenberg, D M

“…The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the…”
Get full text